NCT01223352

The YODA Project · An Open-label, Prospective Multicenter Study to Assess the Pharmacokinetics, Tolerability, Safety and Efficacy of the Pediatric Formulation ...

A bosentan pharmacokinetic study to investigate dosing regimens in ...

... NCT01223352). It was predominantly designed as a PK study, and patients were enrolled in 30 centres in Europe, North America, Latin America, Australia, Asia ...

Bosentan Completed Phase 3 Trials for Pulmonary Arterial ...

NCT01223352. Effects of Two Dosing Regimens of Bosentan in Children With Pulmonary Arterial Hypertension. Bosentan (DB00559) · NCT00319267. Bosentan in Children ...

A Post-hoc Analysis From the FUTURE 3 Study - PMC - NCBI

... (NCT01223352). The full eligibility criteria and methodology of FUTURE 3 have been published (13). Briefly, pediatric patients aged ≥3 ...

Trial Review - ANZCTR - Registration

Registration number. NCT01223352 ; Ethics application status ; Date submitted. 12/10/2010 ; Date registered. 19/10/2010 ; Date last updated. 11/12/2017.

Comparison Between Dried Blood Spot and Plasma Bosentan ...

The FUTURE-3 study (NCT01223352) was a phase III paediatric PK trial conducted primarily to compare 2 bosentan dosing regimens in children aged from 3 months to ...

Bosentan Pharmacokinetics in Pediatric Patients with Pulmonary ...

This was an open-label, randomized, multiple-dose, phase 3 study (NCT01223352), conducted at 30 expert pediatric centers. For the ...

Pulmonary Artery Hypertension Completed Phase 3 Trials for ...

NCT01223352. Effects of Two Dosing Regimens of Bosentan in Children With Pulmonary Arterial Hypertension, Treatment. Bosentan (DB00559) · NCT00319267. Bosentan ...

Pulmonary Arterial Hypertension Archives - The YODA Project

NCT01223352 – An Open-label, Prospective Multicenter Study to Assess the Pharmacokinetics, Tolerability, Safety and Efficacy of the Pediatric Formulation of ...

Comparison Between Dried Blood Spot and Plasma Bosentan ...

FUTURE-3 study (NCT01223352) was a phase III paediatric PK trial conducted primarily to compare 2 bosentan dosing regimens in children aged from 3 months to ...

(PDF) A bosentan pharmacokinetic study to investigate dosing ...

... NCT01223352). It was. predominantly designed as a PK study, and patients were. enrolled in 30 centres in Europe, North America, Latin. America ...

https://www.frontiersin.org/journals/pediatrics/articles/10.3389/fped ...

... (NCT01223352). The full eligibility criteria and methodology of FUTURE 3 have been published (13). Briefly, pediatric ...

Pulmonary Hypertension, Primary, 1 - MalaCards

... NCT01223352, Phase 3, bosentan. 93, AMBITION: A Randomised, Multicenter Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With ...

Database of Drug Development for Rare Diseases - DDrare

NCT01223352 (ClinicalTrials.gov), March 8, 2011, 12/10/2010, Effects of Two Dosing Regimens of Bosentan in Children With Pulmonary Arterial Hypertension, An ...

Bosentan hydrate | ET1 Receptor Antagonist - MedchemExpress.com

NCT01223352, Actelion. Pulmonary Arterial Hypertension. March 8, 2011, Phase 3. NCT01779609, Radboud University Medical Center|Actelion. Type 2 Diabetes ...

Summary of bosentan pharmacokinetic parameters by dosing ...

... (NCT01223352). The full eligibility criteria and methodology of FUTURE 3 have been published (13) . Briefly, pediatric patients aged ≥3 months to <12 years ...

Heritable Pulmonary Arterial Hypertension (FPAH) - MalaCards

NCT01223352, Phase 3, bosentan. 56, A Multicenter, Open-label, Single-sequence Cross-over Study to Assess Safety, Tolerability, and Pharmacokinetics of ...

Pulmonary arterial hypertension - MGeND

NCT01223352, Completed, Phase 3, Effects of Two Dosing Regimens of Bosentan in Children With Pulmonary Arterial Hypertension, March 8, 2011, August 19, 2013.

ClinicalTrials.gov records: Completed | United States | Phase 3

NCT01223352, No Study Results Posted, Drug: bosentan|Drug: bosentan, Industry, 01/31/2011, 12/10/2010, 08/31/2013, 09/30/2013, 09/30/2013, 10/31/2013, 30 ...

(PDF) Management of Pulmonary Hypertension in Neonates with ...

... NCT01223352). An important downside of bosentan is its oral administration route; this makes its use less attractive in ventilated neonates with upper ...